Chemoradiation Including Paclitaxel for Locally Recurrent Muscle-invasive Bladder Cancer in Elderly Patients

In Vivo. 2017 Mar-Apr;31(2):239-241. doi: 10.21873/invivo.11051.

Abstract

Background/aim: To evaluate outcomes and toxicities of chemoradiation with a less intensive paclitaxel regimen for locally recurrent bladder cancer.

Patients and methods: Three elderly patients received simultaneous chemoradiation for recurrent muscle-invasive bladder cancer. Chemotherapy included two courses (three times 25 mg/m2 over 1.5 weeks) of paclitaxel. Radiotherapy doses were 59.4 Gy to the bladder and 50.4 Gy to regional lymph nodes. Survival, local control and toxicities were retrospectively evaluated.

Results: One patient died after 71 months, two were alive after 69 and 98 months, respectively. No local recurrence was not observed. Five-year survival and local control rates were 100%. Two patients experienced grade 1 acute dysuria, one patient grade 1 diarrhea. Late toxicities were also mild; two patients had grade 1 dysuria.

Conclusion: Chemoradiation with a less intensive paclitaxel regimen resulted in excellent 5-year results and was very well tolerated. It may be a reasonable option for elderly patients who cannot tolerate more intensive approaches.

Keywords: Muscle-invasive bladder cancer; chemoradiation; local recurrence; outcomes; paclitaxel; toxicities.

MeSH terms

  • Aged
  • Chemoradiotherapy / adverse effects
  • Chemoradiotherapy / methods
  • Dysuria / etiology
  • Follow-Up Studies
  • Gastrointestinal Diseases / etiology
  • Humans
  • Infusions, Intravenous
  • Muscles / pathology*
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local
  • Paclitaxel / administration & dosage
  • Paclitaxel / adverse effects
  • Paclitaxel / therapeutic use*
  • Premedication
  • Radiotherapy / methods*
  • Radiotherapy Dosage
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / therapy*

Substances

  • Paclitaxel